Colchicine Plus Rosuvastatin/Ezetimibe for Residual Cardiovascular Risk: Mechanistic Rationale, Safety Concerns and Research Priorities
DOI:
https://doi.org/10.52340/GBMN.2026.01.01.180Keywords:
Atherosclerosis, Colchicine, Ezetimibe, Inflammation, RosuvastatinAbstract
Atherosclerosis, a major global health challenge, is driven by both abnormal lipid metabolism and systemic inflammation. Although combination hypolipidemic therapy, such as HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors and cholesterol-absorption inhibitors, has proven effective in lowering cholesterol levels, a significant residual cardiovascular risk, driven by systemic inflammation, persists. Colchicine, a time-tested anti-inflammatory drug that modulates the NOD-like receptor protein 3 (NLRP3) inflammasome pathway, has recently been approved and supported by major guidelines for secondary cardiovascular prevention. However, there is currently a lack of direct scientific evidence regarding the co- administration of colchicine with potent dual lipid-lowering therapy (rosuvastatin/ezetimibe). This narrative review outlines the mechanistic rationale for this triple-combination approach. Current evidence supports both intensive LDL-C (low-density lipoprotein cholesterol) lowering and inflammation-targeted therapy as important strategies in ASCVD (atherosclerotic cardiovascular disease) prevention; however, direct clinical evidence for colchicine combined with rosuvastatin/ezetimibe remains insufficient. Future trials should evaluate whether this combination improves lipid and inflammatory biomarkers, plaque-stability markers, and cardiovascular outcomes, while carefully monitoring for muscle toxicity and the risk of drug-drug interactions.References
Residual lipid risk: Persistent ASCVD risk due to LDL-C, non-HDL-C, ApoB (Apolipoprotein B), Lp(a) (Lipoprotein(a)), triglyceride-rich remnants, or oxidized LDL despite therapy (Indicators: LDL-C, ApoB, non-HDL-C, Lp(a), TG(Triglycerides), oxLDL).
Residual inflammatory risk: Persistent ASCVD risk associated with vascular inflammation despite adequate lipid lowering (Indicators: hs-CRP (high-sensitivity C-reactive protein), IL-6 (Interleukin-6), IL-1β (Interleukin-1 beta) pathway activation).
Residual thrombotic risk: Persistent risk related to platelet activation, coagulation, NETosis, and endothelial dysfunction (Indicators: D-dimer, platelet activity, NET markers).
Residual metabolic risk: Risk driven by diabetes, obesity, insulin resistance, fatty liver, and metabolic syndrome (Indicators: HbA1c, insulin resistance, waist circumference).
Strong clinical evidence: LDL-C reduction by rosuvastatin/ezetimibe.
Strong/moderate clinical evidence: Colchicine reduction of clinical events in chronic CAD.
Moderate biomarker evidence: CRP/IL-6 reduction.
Mechanistic/limited clinical evidence: MMP modulation.
Mechanistic evidence: ET-1 modulation.
Emerging mechanistic evidence: NETosis suppression.
Hypothesis only: Triple-combination superiority.
Optimize lifestyle and standard secondary prevention.
Initiate high-intensity statin therapy.
Add ezetimibe if LDL-C/ApoB remains above therapeutic goal.
Assess residual inflammatory risk utilizing hs-CRP.
Consider low-dose colchicine only if inflammatory risk persists, and there are no contraindications.
Routinely monitor CK, renal function, liver enzymes, symptoms, and potential drug interactions.
Lechner K, von Schacky C, McKenzie AL, et al. Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors. Eur J Prev Cardiol. 2020;27(4):394-406. doi:10.1177/2047487319869400
Yao BC, Meng LB, Hao ML, Zhang YM, Gong T, Guo ZG. Chronic stress: a critical risk factor for atherosclerosis. J Int Med Res. 2019;47(4):1429-1440. doi:10.1177/0300060519826820
Gao G, Wonbin P, Kim B, et al. Construction of a Novel In Vitro Atherosclerotic Model from Geometry‐Tunable Artery Equivalents Engineered via In‐Bath Coaxial Cell Printing. Adv Funct Mater. 2020;31:2008878. doi:10.1002/adfm.202008878
Lamb YN. Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs Drugs Devices Interv. 2020;20(4):381-392. doi:10.1007/s40256-020-00421-1
Pradhan A, Bhandari M, Sethi R. Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives. Cardiol Res Pract. 2020;2020:9815016. doi:10.1155/2020/9815016
Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in Cardiovascular Disease: In Depth Review. Circulation. 2022;145(1):61-78. doi:10.1161/CIRCULATIONAHA.121.056171
Nidorf SM, Thompson PL. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Clin Ther. 2019;41(1):41-48. doi:10.1016/j.clinthera.2018.11.016
Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022;23(6):3346. doi:10.3390/ijms23063346
Poznyak AV, Sadykhov NK, Kartuesov AG, et al. Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment. Front Cardiovasc Med. 2022;9:959285. doi:10.3389/fcvm.2022.959285
Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020;21(5):1835. doi:10.3390/ijms21051835
Fu X, Zong T, Yang P, et al. Nicotine: Regulatory roles and mechanisms in atherosclerosis progression. Food Chem Toxicol. 2021;151:112154. doi:10.1016/j.fct.2021.112154
Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415-424. doi:10.1016/j.jacl.2019.04.011
Vinci P, Panizon E, Tosoni LM, et al. Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. Int J Mol Sci. 2021;22(21):11687. doi:10.3390/ijms222111687
Paseban M, Butler AE, Sahebkar A. Mechanisms of statin-induced new-onset diabetes. J Cell Physiol. 2019;234(8):12551-12561. doi:10.1002/jcp.28123
Li Y, Zhang Y, Lu J, Yin Y, Xie J, Xu B. Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy. J Cell Mol Med. 2021;25(17):8087-8094. doi:10.1111/jcmm.16798
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(2):199-207.e15. doi:10.1016/j.ahj.2013.03.018
Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128(11):1728-1746. doi:10.1161/CIRCRESAHA.121.319077
Ridker PM, Everett BM, Pradhan A, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;380(8):752-762. doi:10.1056/NEJMoa1809798
Tian X, Wong W, Xu A, et al. Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. Br J Pharmacol. 2011;164(2b):598-606. doi:10.1111/j.1476-5381.2011.01416.x
U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease. Agepha Pharma US. June 20, 2023. Accessed July 13, 2026. https://us.agephapharma.com/blog/2023/06/20/us-fda-approves-first-anti-inflammatory-drug-for-cardiovascular-disease/
Meyer-Lindemann U, Mauersberger C, Schmidt AC, et al. Colchicine Impacts Leukocyte Trafficking in Atherosclerosis and Reduces Vascular Inflammation. Front Immunol. 2022;13:898690. doi:10.3389/fimmu.2022.898690
Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res. 2009;26(4):958-964. doi:10.1007/s11095-008-9798-6
Cimmino G, Loffredo FS, De Rosa G, Cirillo P. Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence. Int J Mol Sci. 2023;24(3):2483. doi:10.3390/ijms24032483
Misra A, Psaltis PJ, Nidorf SM. Editorial: Role of colchicine in atherosclerosis. Front Cardiovasc Med. 2024;11:1516185. doi:10.3389/fcvm.2024.1516185
Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis. 2012;33(1):88-94. doi:10.1007/s11239-011-0637-y
Kajikawa M, Higashi Y, Tomiyama H, et al. Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. Int J Cardiol. 2019;281:35-39. doi:10.1016/j.ijcard.2019.01.054
d’Entremont MA, Lee SF, Mian R, et al. Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction. Am Heart J. 2024;275:173-182. doi:10.1016/j.ahj.2024.06.007
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372
Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. doi:10.1016/j.jacc.2012.10.027
Martínez GJ, Robertson S, Barraclough J, et al. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J Am Heart Assoc. 2015;4(8):e002128. doi:10.1161/JAHA.115.002128
Tucker B, Kurup R, Barraclough J, et al. Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study. Clin Ther. 2019;41(10):2172-2181. doi:10.1016/j.clinthera.2019.07.015
Demidowich AP, Levine JA, Apps R, et al. Colchicine’s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial. Int J Obes. 2020;44(8):1793-1799. doi:10.1038/s41366-020-0598-3
Vaidya K, Arnott C, Martínez GJ, et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):305-316. doi:10.1016/j.jcmg.2017.08.013
Zhang RS, Weber BN, Araiza-Garaygordobil D, Garshick MS. Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation. Curr Cardiol Rep. 2024;26(5):423-434. doi:10.1007/s11886-024-02049-y
Schwarz N, Fernando S, Chen YC, et al. Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. FASEB J Off Publ Fed Am Soc Exp Biol. 2023;37(4):e22846. doi:10.1096/fj.202201469R
Sabanis N, Paschou E, Drylli A, Papanikolaou P, Zagkotsis G. Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt. CEN Case Rep. 2021;10(4):570-575. doi:10.1007/s13730-021-00598-7
Liu Y, Wei C, Yuan Y, Zou D, Wu B. Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004-2023. Front Pharmacol. 2024;15:1418498. doi:10.3389/fphar.2024.1418498
Demidowich AP, Wolska A, Wilson SR, et al. Colchicine’s Effects on Lipoprotein Particle Concentrations in Adults with Metabolic Syndrome: A Secondary Analysis of a Randomized Controlled Trial. J Clin Lipidol. 2019;13(6):1016-1022.e2. doi:10.1016/j.jacl.2019.10.011
